Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2016 - 2019)

Historic Current Deferred Revenue for Ultragenyx Pharmaceutical (RARE) over the last 4 years, with Q1 2019 value amounting to $69000.0.

  • Ultragenyx Pharmaceutical's Current Deferred Revenue fell 9045.64% to $69000.0 in Q1 2019 from the same period last year, while for Mar 2019 it was $69000.0, marking a year-over-year decrease of 9045.64%. This contributed to the annual value of $6.0 million for FY2017, which is 165542.52% up from last year.
  • According to the latest figures from Q1 2019, Ultragenyx Pharmaceutical's Current Deferred Revenue is $69000.0, which was down 9045.64% from $1.2 million recorded in Q2 2018.
  • In the past 5 years, Ultragenyx Pharmaceutical's Current Deferred Revenue ranged from a high of $6.0 million in Q4 2017 and a low of $69000.0 during Q1 2019
  • In the last 4 years, Ultragenyx Pharmaceutical's Current Deferred Revenue had a median value of $637000.0 in 2017 and averaged $1.0 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Current Deferred Revenue surged by 165542.52% in 2017 and then plummeted by 9045.64% in 2019.
  • Over the past 4 years, Ultragenyx Pharmaceutical's Current Deferred Revenue (Quarter) stood at $341000.0 in 2016, then surged by 1655.43% to $6.0 million in 2017, then plummeted by 79.22% to $1.2 million in 2018, then plummeted by 94.45% to $69000.0 in 2019.
  • Its Current Deferred Revenue was $69000.0 in Q1 2019, compared to $1.2 million in Q2 2018 and $723000.0 in Q1 2018.